When a patent expires, a market transforms — and on March 21, the moment semaglutide's legal protection lapsed, India's pharmaceutical industry moved with the speed of a market that had long been waiting. Novo Nordisk, the Danish maker of Ozempic, now confronts a familiar but humbling reckoning: the drug it once sold for nearly ₹11,000 a month is being offered by domestic competitors for as little as ₹1,290. The company's anticipated price cut of 30 to 50 percent is less a strategic choice than an acknowledgment that the world has already changed around it.
Novo Nordisk to slash Ozempic prices as Indian generics flood market
A drug that cost ₹11,000 is now accessible at a quarter of that price.
Mark
Why does Novo Nordisk need to cut prices at all? They invented the drug. Can't they just maintain their position?
Mimi
They could try, but they'd lose customers fast. When a dozen competitors show up with prices 50 to 75 percent lower, staying at ₹11,000 a month means you're pricing yourself out of the market. It's not about what's fair—it's about what sticks.
Mark
So this is a race to the bottom?
Mimi
Not quite. It's a race to find the floor. Novo's cutting to ₹5,000-6,000, which is still higher than most generics. They're betting they can keep customers who trust the brand or want the original formulation, even at a premium.
Mark
What about the smaller Indian companies pricing at ₹1,290? How do they make money at that price?
Mimi
Scale and lower overhead. They don't have Novo's research costs or global infrastructure. They're manufacturing a known molecule in a high-volume market. The margins are thin, but the volume can be enormous.
Mark
Does this actually help patients?
Mimi
Dramatically. A drug that cost ₹11,000 is now accessible at a quarter or fifth of that price. For a chronic condition like diabetes or weight management, that's the difference between affording treatment and not.
Mark
What happens to Novo's profits?
Mimi
They take a hit. But the alternative—losing market share entirely—is worse. This is about damage control and repositioning for a world where they're no longer the only option.
Mark
Is this unique to India?
Mimi
No. This is what happens in every market when a blockbuster drug loses patent protection and there's a robust generic industry waiting. India just moves faster than most.
Der Puls
- The instant semaglutide's patent expired on March 21, a dozen Indian pharmaceutical companies launched competing generics simultaneously — some priced as low as ₹900 per month, undercutting Novo Nordisk by up to 75 percent.
- Novo Nordisk's silence is telling: the company declined to confirm a price reduction to the Economic Times, offering only a careful non-answer while industry insiders say the cut is already being prepared.
- The competitive pressure is not just from large rivals — Sun Pharma, Dr Reddy's, and Zydus are joined by smaller players like Natco and Eris, making it impossible for Novo to selectively compete against only established peers.
- A planned reduction to ₹5,000–6,000 monthly would protect some volume but compress margins significantly, forcing Novo to bet that brand loyalty and perceived quality will keep patients from switching to cheaper alternatives.
- For millions of Indian patients managing diabetes or obesity, the price war translates into something concrete: a drug once out of reach is rapidly becoming affordable, reshaping who can access GLP-1 therapy.
When a patent expires, a market transforms — and on March 21, the moment semaglutide's legal protection lapsed, India's pharmaceutical industry moved with the speed of a market that had long been waiting. Novo Nordisk, the Danish maker of Ozempic, now confronts a familiar but humbling reckoning: the drug it once sold for nearly ₹11,000 a month is being offered by domestic competitors for as little as ₹1,290. The company's anticipated price cut of 30 to 50 percent is less a strategic choice than an acknowledgment that the world has already changed around it.
On March 21, the day semaglutide's patent expired, Indian pharmaceutical companies did not wait. Sun Pharmaceuticals, Dr Reddy's, Zydus Lifesciences, and a wave of smaller players launched generic versions of the blockbuster drug almost immediately, pricing their products between ₹900 and ₹4,200 per month — a fraction of Novo Nordisk's ₹8,800 to ₹11,175 monthly price for Ozempic.
Novo Nordisk is now preparing to respond. Industry sources indicate the Danish company plans to cut its price by nearly half, bringing Ozempic to somewhere between ₹5,000 and ₹6,000 monthly. The company has not confirmed this publicly, offering only a guarded non-response when pressed. But the direction is clear: hold enough of the market by closing the price gap, even at the cost of significantly lower margins.
What distinguishes this moment is the speed and coordination of the Indian generic industry's response. These companies did not scramble after the patent fell — they launched on day one, suggesting months of preparation behind the scenes. The market had been coiled, waiting for the legal barrier to lift.
For patients, the outcome is straightforward: a drug synonymous with weight loss and diabetes management is becoming dramatically more accessible. For Novo Nordisk, the calculus is harder. Selling more units at lower profit per unit may be the only viable path, but whether its brand retains enough pull to justify even a reduced premium — against a dozen aggressive competitors — remains the central question of this unfolding price war.
The patent on semaglutide expired on March 21, and within hours, Indian pharmaceutical companies flooded the market with generic versions of the blockbuster drug. Novo Nordisk, which had been selling Ozempic at ₹8,800 to ₹11,175 per month, now faces a choice: hold the line or retreat. According to industry sources, the Danish company is preparing to cut its price by nearly half, bringing Ozempic down to somewhere between ₹5,000 and ₹6,000 monthly—still a premium over the Indian generics, but close enough to remain competitive.
The math is straightforward. Sun Pharmaceuticals priced its weekly semaglutide injection at ₹900 to ₹2,000 depending on indication. Dr Reddy's Laboratories set its version, called Obeda, at ₹4,200 per month. Zydus Lifesciences came in at an average of ₹2,200. And smaller players like Natco and Eris pushed even lower, offering vials for as little as ₹1,290 monthly. When a dozen competitors arrive simultaneously with prices that undercut you by 50 to 75 percent, the calculus changes fast.
Novo Nordisk has not officially confirmed the price reduction. When asked directly by the Economic Times, the company offered only a careful non-answer: they cannot confirm the matter at the moment. But the industry consensus is clear. One insider told the Times that Novo would prefer to compete mainly against large, established pharmaceutical firms rather than a sprawl of smaller players. That preference, however, may not be a luxury the company can afford. The generic flood has already begun.
What makes this moment significant is not just the price war itself, but what it reveals about the Indian pharmaceutical market's capacity to move fast and aggressive. Sun, Dr Reddy's, and Zydus did not wait months to develop their products. They launched on the first day the patent expired. That speed and coordination suggest a market that has been preparing for this moment, ready to capture share the instant the legal barrier fell.
For patients and consumers, the immediate effect is clear: a drug that cost ₹11,000 a month is about to become available for a fraction of that price. For Novo Nordisk, the calculation is more complex. A price cut protects market share but erodes margins. The company is betting that holding onto volume—selling more units at lower profit per unit—is better than ceding the market to competitors. Whether that gamble pays off will depend on how many patients switch to cheaper generics and whether Novo can maintain enough of its customer base to justify the lower price point.
The broader story here is about what happens when a blockbuster drug loses its patent protection in a market with the manufacturing capacity and regulatory infrastructure to move quickly. India's generic pharmaceutical industry has spent decades perfecting the art of rapid-response competition. Semaglutide, a drug that has become synonymous with weight loss and diabetes management, is now subject to the same pressures that have reshaped so many other drug categories in India. The question is not whether prices will fall—they already have. The question is how far they will fall, and whether Novo Nordisk's price cut will be enough to keep it in the game.
Bemerkenswerte Zitate
Novo would prefer to have competition with mostly large competitors in the market and not much of smaller players.— Industry insider
Möchten Sie die ganze Geschichte?
Das Original lesen bei The Economic Times ↗
Health & Medicine